63 results about "INSULIN HUMAN" patented technology

The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein.

The invention discloses expression of human insulin and analogues thereof in a methanol yeast containing dual promoters and a high-efficient preparation method of the human insulin and the analogues thereof, and the method is characterized in that recombinant human insulin and the analogues thereof are prepared by constructing an expression vector containing the dual promoters and engineering cells in host cells of the methanol yeast, and performing the optimal fermentation technology and the high-efficient purification technology, so that the production cost of the recombinant human insulin and the analogues thereof can be effectively reduced.

The invention was involved in expression of human insulin gene, especially for the expression of human insulin gene in Pichia Pastoris GS115 / pPICM#101 whose storage number wais CCTCC NO.M204071. It contained B and A strand synthesis, construction of express plasmid and engineering strain, transform of host cell, filter of transformant and over expression engineering strain, etc. The method left out the difficult procedure, reduced the process steps and shortened time, so the technique was simple. It overexpressed 10-100 folds than the others. It provided one new simple method for human insulin commercial process.

A liquid supplying device for a human insulin injection includes a substrate, a liquid storage chamber, a flow-guiding-and-actuating unit, a sensor and a driving chip. The flow-guiding-and-actuating unit includes a liquid guiding channel having a liquid guiding outlet in fluid communication with a liquid storage outlet of the liquid storage chamber. The sensor contacts with the human skin to measure a blood glucose level contained in sweat. The driving chip is configured to control the actuation of the flow-guiding-and-actuating unit, control open / closed states of the switching valves and receive the measured data from the sensor for determination. By driving the flow-guiding-and-actuating unit, a pressure gradient is generated, and an insulin liquid stored in the liquid storage chamber is transported to the liquid guiding outlet through the liquid guiding channel, flowing into a microneedle patch, and injected into a subcutaneous tissue through a plurality of hollow microneedles.

The invention discloses a serum-free culture medium for mesenchymal stem cells. The serum-free culture medium for the mesenchymal stem cells comprises the following ingredients: fibronectin at the final concentration of 25mu g / ml, basic fibroblast growth factors at the final concentration of 10ng / ml, human epidermal growth factors at the final concentration of 15ng / ml, recombinant human insulin at the final concentration of 1mg / ml, human transferrin at the final concentration of 0.55mg / ml, human blood albumin in a volume ratio of 5 percent, sodium selenite at the final concentration of 0.67mug / ml, L-carnitine at the final concentration of 5mM and resveratrol at the final concentration of 30mu M. When the mesenchymal stem cells are cultured by the serum-free culture medium for the mesenchymal stem cells, animal-derived serum is not contained, so infection risks can be controlled; the L-carnitine and the resveratrol which are added into the serum-free culture medium for the mesenchymalstem cells can effectively improve the growth state of the mesenchymal stem cells; and the growth speed of the mesenchymal stem cells is remarkably improved, and the biological characteristics of themesenchymal stem cells are kept unchanged.

Compositions and methods are provided for screening for compounds that modulate insulin promoter activity. Vectors that express green fluorescent protein under the control of the human insulin promoter are introduced into mouse and human cells in which the insulin promoter is expressed in a glucose-responsive manner. Such cells are then used to screen for compounds that modulate insulin promoter activity.

The invention relates to peptide mass fingerprinting technique for the proteins such as Human insulin and insulin analogs. The insulin analogues can vary at least by one amino acid, which is elusive to distinguish by currently available analytical methods. The invention further allows sequence confirmation of the peptide wherein the run time of the method is forty minutes. This method could be applied for molecules up to 50kDa.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human insulin to result in insulin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.